AZ's Seroquel receives additional approval

The FDA has approved AstraZeneca's Seroquel for depressive episodes associated with bipolar disorder. The drug is already approved to treat manic episodes and is now the only therapy to treat both depressive and manic episodes associated with bipolar disorder. "Treating acute bipolar disorder with a single medication may help patients adhere to their medication regimen," said John Patterson, executive director of development for AstraZeneca, in a press release.

- see this press release for more

PLUS: Schering-Plough has received approval for Noxafil Oral Suspension
for the treatment of oropharyngeal candidiasis (OPC), including infections
refractory to itraconazole and/or fluconazole. Just last month, the FDA approved the therapy for preventing fungal infections in leukemia patients. Report

ALSO: GlaxoSmithKline and Flamel Technologies' once-a-day Coreg has received approval from the FDA for hypertension, post-myocardial infarction left ventricular dysfunction, and heart failure. Release

AND: Altana Pharma has gained FDA approval for Omnaris nasal spray. Report

Suggested Articles

Chi-Med has detailed plans to seek approval from the FDA later this year in part on the strength of data from Chinese phase 3 trial.

The clamor for more transparency from the leading pandemic vaccine contenders has been getting louder.

The role gives one of the driving forces behind Bristol Myers Squibb’s $74 billion takeover of Celgene the chance to help build biotechs.